Blockade of LTC4 synthesis caused by additive inhibition of gIV-PLA2 phosphorylation: Effect of salmeterol and PDE4 inhibition in human eosinophils

Journal of Allergy and Clinical Immunology

Volumn 112, Issue 2, 2003, Pages 404-410

  Meliton, Angelo Y ^a   Muñoz, Nilda M ^a   Liu, Jie ^a   Lambertino, Anissa T ^a   Boetticher, Evan ^a   Myo, Saori ^a   Myou, Shigeharu ^a   Zhu, Xiangdong ^a   Johnson, Malcolm ^b   Leff, Alan R ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Arachidonic acid; cAMP; Eosinophils; gIV PLA2; LTC4; PDE4; 2 agonist

Indexed keywords

ARACHIDONIC ACID; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CYCLIC AMP; CYTOCHALASIN B; CYTOSOLIC GROUP IV PHOSPHOLIPASE A2; FORMYLMETHIONYLLEUCYLPHENYLALANINE; LEUKOTRIENE C4; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHOLIPASE A2; ROLIPRAM; SALMETEROL; UNCLASSIFIED DRUG; 3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; DRUG DERIVATIVE; PHOSPHODIESTERASE INHIBITOR; PHOSPHOLIPASE A; PHOSPHOLIPASE A2 IV; SALBUTAMOL;

ADULT; ARTICLE; CELL ACTIVATION; CELL FUNCTION; CELL SECRETION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EOSINOPHIL; FEMALE; HUMAN; HUMAN CELL; INHIBITION KINETICS; MALE; PRIORITY JOURNAL; BIOSYNTHESIS; CYTOSOL; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ENZYMOLOGY; INTRACELLULAR MEMBRANE; METABOLISM; OSMOLARITY; PHOSPHORYLATION;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; ARACHIDONIC ACID; CYCLIC AMP; CYTOSOL; DRUG SYNERGISM; EOSINOPHILS; FEMALE; HUMANS; INTRACELLULAR MEMBRANES; LEUKOTRIENE C4; MALE; OSMOLAR CONCENTRATION; PHOSPHODIESTERASE INHIBITORS; PHOSPHOLIPASES A; PHOSPHORYLATION; ROLIPRAM;

EID: 0042882541     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2003.1637     Document Type: Article

References (27)

1. Essayan DM. Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol 2001;108:671-80.
2. Giembycz MA. Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here? Drugs 2000;59:193-212.
3. 2-agonists on resident and infiltrating inflammatory cells. J Allergy Clin Immunol 2002;110:S282-90.
4. Cooper N, Teixeira MM, Warneck J, Miotla JM, Wills RE, Macari DM, et al. A comparison of the inhibitory activity of PDE4 inhibitors on leukocyte PDE4 activity in vitro and eosinophil trafficking in vivo. Br J Pharmacol 1999;126:1863-71.
5. Dent G, Giembycz MA, Evans PM, Rabe KF, Barnes PJ. Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibitors of type IV phosphodiesterase: interaction with the beta adrenoceptor agonist albuterol. J Pharmacol Exp Ther 1994;271:1167-74.
6. Berends C, Dijkhuizen B, de Monchy JG, Dubois AE, Gerritsen J, Kauffman HF. Inhibition of PAF-induced expression of CD11b and shedding of L- selectin on human neutrophils and eosinophils by the type IV selective PDE inhibitor, rolipram. Eur Respir J 1997;10:1000-7.
7. Fonteh AN, Winkler JD, Torphy TJ, Heravi J, Undem BJ, Chilton FH. Influence of isoproterenol and phosphodiesterase inhibitors on platelet-activating factor biosynthesis in the human neutrophil. J Immunol 1993;151:339-50.
8. Crocker IC, Townley RG, Khan MM. Phosphodiesterase inhibitors suppress proliferation of peripheral blood mononuclear cells and interleukin-4 and -5 secretion by human T-helper type 2 cells. Immunopharmacology 1996;31:223-35.
9. Kim DH, Lerner A. Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia. Blood 1998;92:2484-94.
10. Tenor H, Hatzelmann A, Kupferschmidt R, Stanciu L, Djukanovic R, Schudt C, et al. Cyclic nucleotide phosphodiesterase isoenzyme activities in human alveolar macrophages. Clin Exp Allergy 1995;25:625-33.
11. Dent G, Giembycz MA, Rabe KF, Wolf B, Barnes PJ, Magnussen H. Theophylline suppresses human alveolar macrophage respiratory burst through phosphodiesterase inhibition. Am J Respir Cell Mol Biol 1994;10:565-72.
12. Ezeamuzie CI. Requirement of additional adenylate cyclase activation for the inhibition of human eosinophil degranulation by phosphodiesterase IV inhibitors. Eur J Pharmacol 2001;417:11-8.
13. 4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects. Br J Pharmacol 1996;118:1727-35.
14. Gleich GJ. The eosinophil and bronchial asthma: current understanding. J Allergy Clin Immunol 1990;85:422-36.
15. Seminario MC, Gleich GJ. The role of eosinophils in the pathogenesis of asthma. Curr Opin Immunol 1994;6:860-4.
16. Brown JK, Leff AR, Frey MJ, Reed BR, Lazarus SC, Shields R, et al. Characterization of tracheal mast cell reactions in vivo: inhibition by a beta-adrenergic agonist. Am Rev Respir Dis 1982;126:842-8.
17. Munoz NM, Rabe KF, Vita AJ, McAllister K, Mayer D, Weiss M, et al. Paradoxical blockade of beta adrenergically mediated inhibition of stimulated eosinophil secretion by salmeterol. J Pharmacol Exp Ther 1995;273:850-4.
18. Leff AR, Herrnreiter A, Naclerio RM, Baroody FM, Handley DA, Munoz NM. Effect of enantiomeric forms of albuterol on stimulated secretion of granular protein from human eosinophils. Pulm Pharmacol Ther 1997;10:97-104.
19. 2-adrenergic receptor. J Biol Chem 1997;272:7338-44.
20. Gantner F, Tenor H, Gekeler V, Schudt C, Wendel A, Hatzelmann A. Phosphodiesterase profiles of highly purified human peripheral blood leukocyte populations from normal and atopic individuals: a comparative study. J Allergy Clin Immunol 1997;100:527-35.
21. Hansel TT, De Vries IJ, Iff T, Rihs S, Wandzilak M, Betz S, et al. An improved immunomagnetic procedure for the isolation of highly purified human blood eosinophils. J Immunol Methods 1991:145:105-10.
22. 2 activation in arachidonic acid metabolism in human eosinophils. J Immunol 2001:167:461-8.
23. 4 synthesis in human eosinophils caused by CD3-stimulated Th2-like cells in vitro. Am J Physiol Lung Cell Mol Physiol 2000;278:L1172-9.
24. 2. Biochem Pharmacol 1998;55:975-85.
25. Aoki M, Yamamoto S, Kobayashi M, Ohga K, Kanob H, Miyata K, et al. Antiasthmatic effect of YM976, a novel PDE4 inhibitor, in guinea pigs. J Pharmacol Exp Ther 2001;297:165-73.
26. Ndukwu IM, Naureckas ET, Maxwell C, Waldman M, Leff AR. Relationship of cellular transmigration and airway response after allergen challenge. Am J Respir Crit Care Med 1999;160:1516-24.
27. 2-inhibition. Nat Immunol 2001;2:145-9.